Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2017										Related Pages
										Return to Main Menu
Table 24. Characteristics of Tuberculosis Cases in GENType Clusters1, by Alert Levels Based on Log-Likelihood Ratios (LLR)2: United States, 2015–2017
Table 24. Characteristics of Tuberculosis Cases in GENType Clusters, by Alert Levels Based on Log-Likelihood Ratios (LLR): United States, 2015-2017
Case Characteristics
Unique
Clustered
Alert Levels for Clustered Cases3Non-alerted (LLR <5)
Medium (LLR 5 – <10)
High  (LLR ≥10)No.
(%)
No.
(%)
No.
(%)
No.
(%)
No.
(%)**Total**
**16,770**
**79.7**
**4,259**
**20.3**
**2,473**
**58.1**
**1,036**
**24.3**
**750**
**17.6****Origin of Birth**U.S-born
4,169
65.7
2,179
34.3
869
39.9
664
30.5
646
29.6Non-U.S.–born
12,585
85.9
2,072
14.1
1,598
77.1
371
17.9
103
5.0Unknown or Missing
16
66.7
8
33.3
6
75.0
1
12.5
1
12.5**Race and Ethnicity**Hispanic or Latino
4,524
77.4
1,323
22.6
823
62.2
355
26.8
145
11.0American Indian/Alaska Native
133
46.5
153
53.5
17
11.1
51
33.3
85
55.6Asian
6,608
86.8
1006
13.2
868
86.3
108
10.7
30
3.0Black or African American
3,075
72.2
1,185
27.8
500
42.2
325
27.4
360
30.4Native Hawaiian/Other Pacific Islander
123
63.4
71
36.6
43
60.6
10
14.1
18
25.4White
2,144
81.6
483
18.4
207
42.9
172
35.6
104
21.5Multiple Race
116
80.6
28
19.4
9
32.1
11
39.3
8
28.6Unknown or Missing
47
82.5
10
17.5
6
60.0
4
40.0
0
0.0**Age Group (Years)**0–4
85
43.1
112
56.9
49
43.8
42
37.5
21
18.85–14
116
61.1
74
38.9
42
56.8
16
21.6
16
21.615–24
1,554
76.1
488
23.9
282
57.8
129
26.4
77
15.825–44
5,056
78.8
1,361
21.2
746
54.8
370
27.2
245
18.045–64
5,060
76.8
1,525
23.2
859
56.3
348
22.8
318
20.9≥65
4,894
87.5
699
12.5
495
70.8
131
18.7
73
10.4Unknown**Disease Site**Pulmonary Only
11,889
77.8
3,399
22.2
1,923
56.6
843
24.8
633
18.6Extrapulmonary
2,911
87.5
415
12.5
279
67.2
92
22.2
44
10.6Both
1,961
81.6
442
18.4
269
60.9
101
22.9
72
16.3Unknown
9
75.0
3
25.0
2
66.7
0
0.0
1
33.3**Sputum Smear**Positive
7,555
76.6
2,312
23.4
1,285
55.6
621
26.9
406
17.6Negative
6,815
82.2
1,478
17.8
914
61.8
292
19.8
272
18.4Not Done
2,378
83.6
467
16.4
273
58.5
122
26.1
72
15.4Unknown or Missing
22
91.7
2
8.3
1
50.0
1
50.0
0
0.0**Cavitary Disease4**Yes
154
76.2
48
23.8
25
52.1
14
29.2
9
18.8No
1,386
81.0
326
19.0
200
61.3
73
22.4
53
16.3Unknown or Missing**Homeless Within Past Year**Yes
628
56.8
478
43.2
195
40.8
119
24.9
164
34.3No
16,051
81.0
3,757
19.0
2,264
60.3
909
24.2
584
15.5Unknown or Missing
91
79.1
24
20.9
14
58.3
8
33.3
2
8.3**Excess Alcohol Use Within the Past Year**Yes
1,385
62.7
823
37.3
329
40.0
254
30.9
240
29.2No
15,157
81.8
3,370
18.2
2,102
62.4
762
22.6
506
15.0Unknown or Missing
228
77.6
66
22.4
42
63.6
20
30.3
4
6.1**Injecting Illicit Drug Use Within Past Year**Yes
170
59.9
114
40.1
42
36.8
42
36.8
30
26.3No
16,410
80.1
4,067
19.9
2,380
58.5
973
23.9
714
17.6Unknown or Missing
190
70.9
78
29.1
51
65.4
21
26.9
6
7.7**Non-Injecting Illicit Drug Use Within Past Year**Yes
877
57.5
649
42.5
260
40.1
195
30.0
194
29.9No
15,704
81.6
3,537
18.4
2,167
61.3
821
23.2
549
15.5Unknown or Missing
189
72.1
73
27.9
46
63.0
20
27.4
7
9.6**Resident of a Correction Facility at the Time of Diagnosis**Yes
463
70.2
197
29.8
94
47.7
50
25.4
53
26.9No
16,192
80.1
4,018
19.9
2,353
58.6
970
24.1
695
17.3Unknown or Missing
115
72.3
44
27.7
26
59.1
16
36.4
2
4.5**HIV Status**Positive
809
76.0
255
24.0
135
52.9
56
22.0
64
25.1Negative
14,089
79.4
3,660
20.6
2,110
57.7
908
24.8
642
17.5Refused
397
86.3
63
13.7
46
73.0
12
19.0
5
7.9Not Offered
991
82.2
215
17.8
136
63.3
46
21.4
33
15.3Unknown, Missing or Indeterminate
484
88.0
66
12.0
46
69.7
14
21.2
6
9.1**Multidrug-Resistant TB**Yes
245
81.1
57
18.9
36
63.2
7
12.3
14
24.6No
15,893
79.8
4,027
20.2
2,337
58.0
982
24.4
708
17.6Unknown or Missing
632
78.3
175
21.7
100
57.1
47
26.9
28
16.01GENType clusters have two or more cases with matching spoligotype and 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat type (MIRU-VNTR) within a county during the specified 3-year time period.2Alert levels are based on a log-likelihood ratio (LLR), which calculates the geographical concentration of a genotype in a county compared to the rest of the country during a 3-year period.3 There were 4,259 cases in 1,409  alerted clusters: 750 cases were in 76 (5.4%) high alert clusters; 1,036 cases were in 335 (23.8%) medium alert clusters, and 2,473 cases were in 998  (70.8%) non-alert clusters.4 Cavitary disease only assessed for persons with pulmonary TB and an abnormal x-ray.
**Note:** Case counts for race categories (American Indian/Alaska Native, Asian, black/African American, Native Hawaiian/Other Pacific Islander, and white) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does not include persons of Hispanic ethnicity.
							
					
						Page last reviewed:  October 22, 2018					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue